IMPORTANT: There is a lot to consider with genetic testing. Please review important information about Carrier Status* and Genetic Health Risk* reports. Before purchasing, review important information at 23andme.com/test-info.
WHAT YOU GET: At-home DNA test kit. Access to Health + Ancestry Service that can help give you a more complete picture of your health with insights from your genetic data. Personalized genetic insights and tools that can help make it easier for you to take action on your health. Includes FDA-authorized reports and full access to our Ancestry Service.
HEALTH FEATURES: Our personalized health reports use science-backed data to show how your DNA can affect your likelihood of developing certain health conditions.* Wellness reports show how your DNA relates to your lifestyle. Carrier Status* reports can show if you're a carrier for genetic variants linked to certain inherited health conditions. Use insights from these genetic reports to help you make informed decisions to fuel your health journey.
SIMPLE & EASY: Genetic testing in 3 simple steps. No blood, no needles. Our home-based saliva collection kit is all you need. We have made the process as simple as possible. Spit in the provided tube, register your kit using the barcode, and return the saliva sample back to our lab in the pre-paid package. Get results back in 4-5 weeks. Your Health + Ancestry kit already includes access to the basic 23andMe Ancestry Service, and is upgradeable to our premium 23andMe+ Membership.
PRIVATE AND PROTECTED: Know that you are in control of your DNA. Discovery should never come at the expense of privacy. Your data is encrypted, protected, and under your control. You decide what you want to learn and what you want to share. Subject to 23andMe’s Terms of Service at 23andme.com/tos and Privacy Statement at 23andme.com/about/privacy.
* The 23andMe PGS test includes health predisposition and carrier status reports. Health predisposition reports include both reports that meet FDA requirements for genetic health risks and reports which are based on 23andMe research and have not been reviewed by the FDA. The test uses qualitative genotyping to detect select clinically relevant variants in the genomic DNA of adults from saliva for the purpose of reporting and interpreting genetic health risks and reporting carrier status. It is not intended to diagnose any disease. Your ethnicity may affect the relevance of each report and how your genetic health risk results are interpreted. Each genetic health risk report describes if a person has variants associated with a higher risk of developing a disease, but does not describe a person?s overall risk of developing the disease. The test is not intended to tell you anything about your current state of health, or to be used to make medical decisions, including whether or not you should take a medication, how much of a medication you should take, or determine any treatment. Our carrier status reports can be used to determine carrier status, but cannot determine if you have two copies of any genetic variant. These carrier reports are not intended to tell you anything about your risk for developing a disease in the future, the health of your fetus, or your newborn child's risk of developing a particular disease later in life. For certain conditions, we provide a single report that includes information on both carrier status and genetic health risk. **23andMe PGS Pharmacogenetics reports: The 23andMe test uses qualitative genotyping to detect 3 variants in the CYP2C19 gene, 2 variants in the DPYD gene and 1 variant in the SLCO1B1 gene in the genomic DNA of adults from saliva for the purpose of reporting and interpreting information about the processing of certain therapeutics to inform discussions with a healthcare professional. It does not describe if a person will or will not respond to a particular therapeutic and does not describe the association between detected variants and any specific therapeutic. Our CYP2C19 Pharmacogenetics report provides certain information about variants associated with metabolism of some therapeutics and provides interpretive drug information regarding the potential effect of citalopram and clopidogrel therapy. Results for SLCO1B1 and DPYD and certain CYP2C19 results should be confirmed by an independent genetic test prescribed by your own healthcare provider before taking any medical action. Warning: Test information should not be used to start, stop, or change any course of treatment and does not test for all possible variants that may affect metabolism or protein function. The PGS test is not a substitute for visits to a healthcare professional. Making changes to your current regimen can lead to harmful side effects or reduced intended benefits of your medication, therefore consult with your healthcare professional before taking any medical action. For important information and limitations regarding Pharmacogenetics reports, visit 23andme. com/test-info/pharmacogenetics/ Before you can use 23andMe and see your reports, you must agree to 23andMe's Terms of Service (23andme. com/tos) at the time of registration of your 23andMe kit. Your use of 23andMe is further subject to 23andMe's Privacy Statement (23andme. com/about/privacy). For use in the USA only - kits shipped or used outside the US will be invalidated and no refund will be provided. Kits may not be redistributed or resold. 23andMe Claim Substantiation for \"80% get genetically meaningful health info.\" Date range: August 2020 - August 2021. Source: 23andMe internal data.
